Justet, Aurelien
Zhao, Amy Y.
Kaminski, Naftali
Funding for this research was provided by:
Fond de dotation du Souffle
Philippe Foundation
Bourse de Mobilite CHU de Caen
Bourse de mobilite internationale
NIH (T32GM136651-01)
Veracyte
NIH NHLBI (R01HL141852)
Investigator Initiated
Article History
Received: 21 December 2021
Accepted: 26 May 2022
First Online: 13 June 2022
Declarations
:
: Not applicable.
: Not applicable.
: AZ reports no conflict of interest. AJ reports Grants from Roche and served as consultant to Roche and Boeringher Ingelheim, Galapagos over the last 3 years. NK served as a consultant to Biogen Idec, Boehringer Ingelheim, Third Rock, Pliant, Samumed, NuMedii, Theravance, LifeMax, Three Lake Partners, Optikira, Astra Zeneca, RohBar, Veracyte, Augmanity, CSL Behring, Galapagos and Thyron over the last 3 years, reports Equity in Pliant and Thyron, and Grants from Veracyte, Boehringer Ingelheim, BMS and nonfinancial support from MiRagen and Astra Zeneca. NK has IP on novel biomarkers and therapeutics in IPF licensed to Biotech.